Table 3.
Multivariable Cox proportional hazard regression analysis of patients’ demographic and clinical characteristics and survival (n = 110).
| Variables | n | PFS | OS | ||
|---|---|---|---|---|---|
| HR (95%CI) | P-value | HR(95%CI) | P-value | ||
| ERBB2d16 | 1.462 (1.314-1.806) | 0.01 | 1.255 (1.008-1.442) | 0.05 | |
| High | 43 | ||||
| Low | 67 | ||||
| Vimentin | 1.364 (0.983-1.843) | 0.05 | 1.026 (0.843-1.524) | 0.103 | |
| High | 31 | ||||
| Low | 79 | ||||
| E-cadherin | 0.862 (0.833-1.083) | 0.072 | 0.423 (0.112-0.84) | 0.098 | |
| High | 52 | ||||
| Low | 58 | ||||
| PD-L1 | 1.033 (1.0002-2.112) | 0.035 | 1.021 (0.911-2.312) | 0.062 | |
| High | 34 | ||||
| Low | 76 | ||||
| Sex | 1.071 (0.604-1.352) | 0.641 | 1.113 (0.244-1.313) | 0.77 | |
| Female | 52 | ||||
| Male | 58 | ||||
| Age | 1.048 (0.827-1.282) | 0.886 | 1.245 (0.132-2.1) | 0.892 | |
| ≥ 60 | 14 | ||||
| < 60 | 96 | ||||
| TNM staging: | 1.102 (0.923-1.935) | 0.697 | 1.099 (0.879-1.562) | 0.109 | |
| IV | 12 | ||||
| I-III | 98 | ||||
| Differentiation | 0.759 (0.684-1.171) | 0.073 | 1.242 (0.782-1.293) | 0.113 | |
| Well | 27 | ||||
| Poor | 83 | ||||
| No. of metastases | 1.135 (0.871-1.371) | 0.264 | 1.31 (0.988-1.882) | 0.092 | |
| >1 | 7 | ||||
| =1 | 5 | ||||
PFS, progression free survival; OS, overall survival; HR, hazard ratio; ERBB2, human epidermal growth factor receptor-2; ERBB2d16, ERBB2ΔEx16; PD-L1, programmed death ligand 1.